Navigation Links
Indiana State Legislators Seek Solutions to Combat Illegal Meth Production
Date:9/8/2010

WASHINGTON, Sept. 8 /PRNewswire-USNewswire/ -- Today, the Indiana State Legislature's Criminal Law and Sentencing Policy Study Committee is holding a hearing on how the state can improve its policies for preventing the illegal diversion of pseudoephedrine (PSE) - a key ingredient in leading cold and allergy medicines - for methamphetamine production. The panel will hear a range of policy options, from requiring a prescription for currently accessible medicines like Advil Cold & Sinus, Claritin-D, Sudafed, and Mucinex D, to implementing an electronic tracking system -- at no cost to the state -- to block illegal sales of PSE.

"The residents of Indiana deserve a solution that will help fight the state's meth problem, without placing additional burdens on individuals, families, and the state," said Mandy Hagan, director of state government relations for the Consumer Healthcare Product Association, who is testifying at the hearing on behalf of the leading manufacturers of over-the-counter medicines. "Electronic tracking is the only system that blocks illegal PSE sales while maintaining consumer access to the safe and effective medications they rely on for colds and allergies."

In Indiana, there is currently no mechanism in place to curb the practice of "smurfing," when criminals move from store to store to purchase illegal amounts of PSE to be used in the production of meth. At no cost to the state, electronic tracking (e-tracking) would provide the state's retailers and pharmacists with a consolidated, real-time electronic logbook and blocking system -- accessible only by law enforcement -- that is more effective than current paper logs.  

E-tracking, which has been adopted by 12 states nationwide, will also give local law enforcement officials a powerful investigative tool to track and prevent meth production across state lines. E-tracking allows law enforcement to find previously undiscovered meth labs and helps them identify meth cooks. Most importantly, the system preserves Indianans' over-the-counter access to the PSE medications they use and trust for cold and allergy relief while stopping illegal sales.

According to a poll by David Binder Research, almost two-thirds of Indiana voters surveyed oppose making common cold and allergy medications containing PSE available by prescription (Rx) only, and 82 percent agree that an Rx-only requirement would create an "unnecessary burden" for law-abiding citizens. Further, a large majority of respondents agrees that an Rx-only mandate would significantly increase consumer costs and hurt the state's finances at the worst possible time.

In addition to significant consumer opposition to a prescription mandate, additional economic analyses show that an Rx-only policy would have severe economic and social consequences for citizens of Indiana. Under an Rx-only mandate, if only half of Indianans who rely on these medicines were forced to go to a doctor to obtain a prescription, the cost to the healthcare system in doctor visits would be over $31 million. Additional economic impacts to the state would include lost sales tax revenue and notable cost increases to the state's Medicaid program, as well as state employee and retiree programs.

The Indiana State Retail Association also supports implementation of an electronic tracking system.

David Binder Research has been a source for innovative research for more than 25 years, providing high-quality survey, focus group and media research services to clients throughout the United States. The survey, conducted from January 14-24, involved 368 Indiana state residents aged 18 or over, all of whom voted in the last election, and has a margin-of-error of +/-5.1%.  The survey was sponsored by the Consumer Healthcare Products Association.

CHPA is the 129-year-old-trade association representing U.S. manufacturers and distributors of over-the-counter medicines and nutritional supplements.

www.chpa-info.org


'/>"/>
SOURCE Consumer Healthcare Product Association
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Report on 300 New Medicines in Development for Heart Disease and Stroke Released in Indianapolis
2. Public Art to Complete Transformation of Key Gateway into Indianapolis
3. Indiana Blood Center Taps tw telecom for Data, Internet and IP Telephony Services
4. Total Federal Grant Funds for Indiana Health Information Technology Efforts Climb to Nearly $50 Million; Latest $16 Million Installment Spotlights Indiana Health Information Exchange in Delivering Higher Quality and Higher Value Healthcare Through M
5. Hill-Rom to Present at the INVESTIndiana Investor Conference
6. Zimmer Holdings to Present at INVESTIndiana Equity Conference
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
10. Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 19, 2017  Novartis today announced the publication ... Lung, and Blood Institute (NHLBI) of the National ... patients with treatment-naïve severe aplastic anemia (SAA) achieved ... eltrombopag at the initiation of and concurrently with ... three sequential treatment groups, or cohorts. Cohort 3 ...
(Date:4/18/2017)... MINNEAPOLIS , April 18, 2017 Cogentix ... focused on providing the Urology, Uro/Gyn and Gynecology markets ... for the first quarter ended March 31, 2017 after ... The Company will host a conference call ... day on Tuesday, May 2, 2017 at 4:30 p.m. ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., developer ... series to be presented at the 2017 National Kidney ... today and continues through April 22. Physicians will present ... used to assess risk for acute kidney injury (AKI) ... failure (ADHF). Elevated levels of TIMP-2 ...
Breaking Medicine Technology:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... Phytomer USA ... As a Phytomer Account Manager, Smith’s role is to provide excellent customer ... that make up The Phytomer Group. Smith comes to Phytomer with a wealth of ...
(Date:4/28/2017)... ... April 28, 2017 , ... The National Campaign to ... the Access to Contraception for Women Servicemembers and Dependents Act of 2017. The ... will help to ensure that all members of the Armed Forces receive high ...
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield of New Jersey ... “A” and its outlook as “stable.” At the same time, the ratings agency cautioned ... recent years, dip below “capital adequacy” thresholds required for its strong rating. , “Horizon ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Radiology Business Management ... officers for 2017-2018. The annual board election process has been in place since the ... , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... liability could substantially improve drug safety and minimize the cost of development. In ... ion channel inhibition using cell lines and for cardiac toxicity using induced pluripotent ...
Breaking Medicine News(10 mins):